BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp. successfully completed an $8.5 million offering, selling over 12 million shares at $0.69 each to fund working capital, corporate purposes, and business objectives advancement. This financial boost aims to further the company’s development of novel immunotherapies for cancer treatment. The offering was managed by ThinkEquity as the sole placement agent.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
